MiniMed announced its new Board of Directors following its separation from Medtronic, marking its start as an independent public company focused on diabetes technology. The board includes experts in healthcare, medtech, manufacturing, and governance, supporting MiniMed's mission to improve diabetes management and access to integrated technology. CEO Que Dallara emphasized the board's role in driving growth, innovation, and execution. This leadership transition positions MiniMed to enhance its insulin delivery and glucose monitoring systems for people with diabetes worldwide.
MiniMed shares rose 6.60% to USD 17.92 on Pluang as of Oct 16, 2026 03:21 WIB, reflecting investor interest after its board announcement. The stock's market cap stands at $4.73B with a 52-week range between $10.80 and $23.84. Meanwhile, Medtronic shares gained 1.37% to USD 95.52, with a market cap of $120.53B and a dividend yield of 3.06%.
MiniMed has officially separated from Medtronic, marking its first day as an independent company focused on advancing diabetes care. Medtronic exchanged its shares for MiniMed stock and no longer holds equity in MiniMed. This independence allows Mini...
Medtronic announced that its offer to exchange Medtronic shares for MiniMed Group shares was oversubscribed and has now expired. Medtronic will exchange all remaining 252.8 million MiniMed shares for 55 million Medtronic shares on a pro rata basis, a...
